PSP Research LLC Buys Shares of 20,511 Pharvaris N.V. $PHVS

PSP Research LLC bought a new stake in Pharvaris N.V. (NASDAQ:PHVS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 20,511 shares of the company’s stock, valued at approximately $569,000. Pharvaris makes up about 0.5% of PSP Research LLC’s portfolio, making the stock its 5th largest holding.

Several other institutional investors also recently bought and sold shares of PHVS. Wellington Management Group LLP purchased a new stake in shares of Pharvaris during the third quarter worth about $43,282,000. Paradigm Biocapital Advisors LP boosted its position in Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Pharvaris during the third quarter worth about $15,613,000. Commodore Capital LP boosted its position in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. boosted its position in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares during the last quarter.

Pharvaris Price Performance

NASDAQ:PHVS opened at $28.95 on Wednesday. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -9.10 and a beta of -2.34. The company’s 50-day moving average is $28.26 and its two-hundred day moving average is $26.68. Pharvaris N.V. has a 1-year low of $15.46 and a 1-year high of $33.33.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, equities analysts anticipate that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PHVS has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday. UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Insider Buying and Selling

In other Pharvaris news, Director Robert Glassman sold 10,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $29.82, for a total value of $298,200.00. Following the transaction, the director directly owned 10,500 shares in the company, valued at $313,110. The trade was a 48.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Berndt Modig sold 23,333 shares of the business’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42. Following the completion of the transaction, the chief executive officer owned 142,084 shares in the company, valued at $3,941,410.16. The trade was a 14.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 170,659 shares of company stock worth $5,086,987 over the last ninety days.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.